---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-318078"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2026-07-27T20:10:37+00:00"
generated_at: "2026-07-27T20:11:09.220554+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kymera Therapeutics appoints Terence Rooney as CMO; Jared Gollob retires

## Summary
- Jared Gollob retired as CMO effective July 27, 2026; will remain as advisor through Dec 31, 2026.
- Terence Rooney appointed CMO, previously SVP Portfolio & Asset Management Leader, Immunology at Johnson & Johnson.
- Rooney also held senior immunology R&D roles at Eli Lilly and Roche; contributed to approvals of STELARA, TREMFYA, OLUMIANT.
- Gollob's resignation is for personal reasons and not due to any disagreement with company policies.

## SEC filing metadata
- accession: 0001193125-26-318078
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2026-07-27T20:10:37+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312526318078/0001193125-26-318078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312526318078/d167778d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-318078
- JSON: https://secwatch.observer/filing/0001193125-26-318078.json
- Plain text: https://secwatch.observer/filing/0001193125-26-318078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.